{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Blood Cancer Talks","title":"Episode 69. ASH 2025 Lymphoma Roundup with Dr. Carla Casulo","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/97e98f98\"></iframe>","width":"100%","height":180,"duration":2659,"description":"BloodCancerTalks: ASH 2025 Lymphoma Roundup\nGuest: Dr. Carla Casulo, Associate Professor, Wilmot Cancer Centre, University of Rochester\nAbstracts Discussed\nFollicular Lymphoma\nEPCORE-FL1 (Falchi) - Epcoritamab plus lenalidomide-rituximab (R2) in relapsed/refractory FL\nTheme: Bispecific antibody combinations in R/R FL; comparing to other approaches\n \nDiffuse Large B-Cell Lymphoma (DLBCL) - Elderly/Unfit Patients\nMorningSun (Sharman) - Mosunetuzumab monotherapy in patients ≥80 years or chemo-ineligible\nEPCOR-DLBCL-3 (Vitolo) - Epcoritamab monotherapy in elderly patients\nR-Pola-Glo - Rituximab-polatuzumab-glofitamab combination in older/frail patients\nTheme: Single-agent and combination bispecific strategies for elderly and frail DLBCL patients\n \nDLBCL - First-Line Treatment\nSMART STOP (Westin) - Chemotherapy-free approach using lenalidomide, tafasitamab, rituximab, acalabrutinib (ULTRA regimen)\nFrontMIND - Tafasitamab-lenalidomide added to R-CHOP\nTheme: Chemotherapy-sparing and chemo-intensification strategies in newly diagnosed DLBCL\n \nDLBCL - Relapsed/Refractory\nDALY 2-EU (Borchmann) - Dual CD19/CD20 CAR-T (zamto-cel) versus R-GemOx in transplant-ineligible patients\nTheme: Expanding CAR-T eligibility; treatment selection in transplant-ineligible R/R DLBCL\n \nHodgkin Lymphoma\nSWOG 1826 - 3-year update: Nivolumab-AVD versus brentuximab-AVD\nHD21 - 5-year update: PET-adapted BrECADD versus BEACOPP\nTheme: Long-term outcomes and treatment selection in newly diagnosed Hodgkin lymphoma\n \nBurkitt Lymphoma\nZUMA-25 (Van Dorp) - Brexucabtagene autoleucel (Brexu-cel) in relapsed/refractory Burkitt\nTheme: CAR-T therapy for the challenging population of R/R Burkitt lymphoma\n \nMantle Cell Lymphoma - First-Line\n \nTrAVeRse - Acalabrutinib, venetoclax, rituximab\nGLOVe - Glofitamab, lenalidomide, venetoclax (high-risk MCL)\nBOVen - Zanubrutinib, obinutuzumab, venetoclax (older patients)\nMAVO - Acalabrutinib, venetoclax, obinutuzumab\nWindow-3 - Acalabrutinib-rituximab followed by...","thumbnail_url":"https://img.transistorcdn.com/sqlYzk0Oxhchi1Lmft_9Md8dG97D7hyy2rwRG7COuc0/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzMyMDc4LzE2NTcz/MTQxMDUtYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}